Murata Satoshi, Matsuda Tadashi, Kiguchi Sumiyoshi, Kobayashi Mamoru, Cho Kazutoshi, Okuyama Kazuhiko
Pharmacology Research, R and D, Kissei Pharmaceutical Co., Ltd., Japan.
BJOG. 2005 Jan;112(1):69-74. doi: 10.1111/j.1471-0528.2004.00333.x.
To evaluate the safety of KUR-1246 as a tocolytic agent, we examined the effects of its long term infusion on respiratory and cardiovascular systems and general metabolism in pregnant sheep and their fetuses.
Animal experiment with chronically instrumented ewes and their fetuses.
Center for animal experiments, Hokkaido University School of Medicine, Japan.
Eight Suffolk ewes at 117 to 120 days of gestation.
At 120-124 days of gestation, ewes (n= 4) were infused intravenously for 24 hours with KUR-1246 at 0.03 microg/kg/minute, a dose that completely inhibits oxytocin-induced uterine contractions in pregnant sheep. The controls received saline instead (n= 4). Statistical comparisons were carried out by repeated-measures ANOVA followed by Dunnett's test.
Maternal and fetal values of heart rate, blood pressure, plasma electrolytes, glucose, insulin and non-esterified fatty acid levels, and blood gases and lactate level.
The maternal plasma levels of KUR-1246 increased and reached a plateau at 15 hours or later from the start of the infusion, whereas the fetal levels of it were below the lower limit of quantification (0.1 ng/mL) throughout the experiment. Significant differences over time between the ewes that had received with KUR-1246 and the controls were found for the following parameters: maternal heart rate, blood lactate, plasma glucose, and plasma insulin levels, and fetal plasma glucose and plasma insulin levels (P < 0.05). In the KUR-1246 treated ewes, significant changes from the pre-infusion value were detected in maternal blood lactate and fetal plasma glucose levels within 6 hours from the start of the infusion (P < 0.05). No significant differences were observed in other parameters in either ewes or fetuses.
The physiologic changes induced by a 24-hour infusion of KUR-1246 were transient and considered to be within the compensatory capacity in both pregnant ewes and their fetuses, suggesting that KUR-1246 is a potentially safe tocolytic agent for use by long term infusion.
为评估KUR - 1246作为一种宫缩抑制剂的安全性,我们研究了其长期输注对妊娠绵羊及其胎儿的呼吸、心血管系统和一般代谢的影响。
对慢性植入仪器的母羊及其胎儿进行动物实验。
日本北海道大学医学院动物实验中心。
8只妊娠117至120天的萨福克母羊。
在妊娠120 - 124天时,4只母羊以0.03微克/千克/分钟的剂量静脉输注KUR - 1246 24小时,该剂量可完全抑制妊娠绵羊中催产素诱导的子宫收缩。对照组则输注生理盐水(4只)。采用重复测量方差分析及Dunnett检验进行统计学比较。
母羊和胎儿的心率、血压、血浆电解质、葡萄糖、胰岛素和非酯化脂肪酸水平,以及血气和乳酸水平。
KUR - 1246的母羊血浆水平升高,并在输注开始后15小时或更晚达到平台期,而在整个实验过程中,其胎儿水平低于定量下限(0.1纳克/毫升)。接受KUR - 1246的母羊与对照组在以下参数上随时间存在显著差异:母羊心率、血乳酸、血浆葡萄糖和血浆胰岛素水平,以及胎儿血浆葡萄糖和血浆胰岛素水平(P < 0.05)。在接受KUR - 1246治疗的母羊中,输注开始后6小时内母羊血乳酸和胎儿血浆葡萄糖水平与输注前值相比有显著变化(P < 0.05)。在母羊或胎儿的其他参数上未观察到显著差异。
24小时输注KUR - 1246引起的生理变化是短暂的,并且被认为在妊娠母羊及其胎儿的代偿能力范围内,这表明KUR - 1246是一种长期输注使用时潜在安全的宫缩抑制剂。